Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;74(15):1829-36.
doi: 10.1007/s40265-014-0296-3.

Eliglustat: first global approval

Raewyn M Poole  1
Affiliations
Review

Eliglustat: first global approval

Raewyn M Poole. Drugs. 2014 Oct.

Abstract

Eliglustat [Cerdelga™ (US, EU)], a small-molecule oral glucosylceramide analogue that inhibits the enzyme glucosylceramide synthase has been developed by Genzyme Corporation (a subsidiary of Sanofi) for the treatment of Gaucher disease type 1 in adults. Inhibition of this enzyme reduces the accumulation of the lipid glucosylceramide in the liver, spleen, bone marrow and other organs. Eliglustat received its first global approval in this indication in the US, for use in treatment-naïve and treatment-experienced adult patients. It is also under regulatory review in the EU and Japan. This article summarizes the milestones in the development of eliglustat leading to this first approval for Gaucher disease type 1.

PubMed Disclaimer

References

    1. Ann Pharmacother. 2013 Sep;47(9):1182-93 - PubMed
    1. Drugs Future. 2010 Aug 1;35(8):613-620 - PubMed
    1. Blood. 1993 Sep 1;82(5):1402-9 - PubMed
    1. Blood. 2010 Aug 12;116(6):860-1 - PubMed
    1. Blood. 2010 Aug 12;116(6):893-9 - PubMed

MeSH terms

LinkOut - more resources